Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (3273)	2/4/2003 1:47:08 PM
From: Art M	Read Replies (2) \| Respond to of 37387

I got the IPSU 10K mailed to me last week. what was it I am supposed to be looking for? thanks

To: Crossy who wrote (3273)	2/12/2003 12:23:14 PM
From: Sleepman	Read Replies (1) \| Respond to of 37387

Crossy: This release is a good sign. As I read it, it looks like a $800,000+ order. That will double their quarterly sales. If they come out with more outlets, that will soar. Dan Press Release Source: Dragon Pharmaceuticals Inc. Dragon Launches EPO into the Brazilian Market Wednesday February 12, 8:03 am ET VANCOUVER, Feb. 12 /PRNewswire-FirstCall/ - Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin ("EPO") to Itaca Laboratorios Ltda., ("Itaca") of Brazil. ADVERTISEMENT Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon's EPO in the Brazilian state of Minas, Gerais, which converts to US$ 0.86 million (US$ 0.281057 to 1 Brazilian Real exchange rate on February 4, 2003). The first shipment to Itaca marks the launch of Dragon's EPO into the Brazilian market. "This order followed an audit in 2002 by the Brazilian Health Authority ("ANVISA") inspectors of Dragon's production facility in Nanjing, China. The ANVISA audit has provided valuable feedback to the Nanjing staff as well as the Vancouver management. We have been implementing the necessary steps to elevate our facility to the highest technical and documentary standards expected for today's biotechnology industry anywhere in the world with the help of international experts", said Dr. Alexander Wick, President of Dragon Pharmaceuticals Inc. "Our first order in Brazil demonstrates our commitment to expanding sales into new international markets outside of China," said Dr. Wick, "We have secured licensing agreements with fourteen distribution partners covering more than ninety countries globally and we expect to receive additional product registration approvals throughout the year." Dragon and its licensees are currently seeking regulatory approval for the marketing of the Company's EPO throughout Eastern Europe, Asia, Africa, Latin America and the Middle East. About Dragon Pharmaceuticals Dragon Pharmaceuticals Inc. is a fully integrated, international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon believes that it has become one of the world's lowest cost producers of Erythropoietin (EPO) - a breakthrough drug that has revolutionized the treatment of severe anemia with estimated worldwide sales of US$6 billion in 2001. Dragon is also applying its platform technology to the development of other branded as well as novel protein drugs. Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995: All statements, other than historical facts, included in the foregoing press release are forward-looking statements. These statements are based on management's beliefs and assumptions, and on information currently available to management. Such forward-looking statements include, but are not limited to, the continued growth in sales of EPO and the development of new EPO uses, Dragon's ability to pursue sales in non-patented countries and Dragon's ability to achieve rapid and low cost product approval in China. Forward-looking statements are not guarantees of future performance. They involve risk, uncertainties and assumptions including risks discussed under "Risks Associated With Dragon Pharmaceuticals" in the Company's annual report on Form 10-K, SEC File No.: 0- 27937, all of which are incorporated herein by reference. The Company does not undertake the obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.